

## In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of *Aspergillus* Species<sup>∇</sup>

M. A. Pfaller,<sup>1,2\*</sup> S. A. Messer,<sup>1</sup> L. Boyken,<sup>1</sup> C. Rice,<sup>1</sup> S. Tendolkar,<sup>1</sup>  
 R. J. Hollis,<sup>1</sup> and D. J. Diekema<sup>1,3</sup>

Departments of Pathology<sup>1</sup> and Medicine,<sup>3</sup> Roy J. and Lucille A. Carver College of Medicine, and  
 Department of Epidemiology, College of Public Health,<sup>2</sup> University of Iowa, Iowa City, Iowa 52242

Received 19 March 2008/Returned for modification 4 April 2008/Accepted 12 June 2008

Few data exist to describe in vitro patterns of cross-resistance among large collections of clinical *Aspergillus* isolates, including those of species other than *Aspergillus fumigatus*. We examined 771 *Aspergillus* spp. clinical isolates collected from 2000 to 2006 as part of a global antifungal surveillance program (553 *A. fumigatus*, 76 *A. flavus*, 59 *A. niger*, 35 *A. terreus*, and 24 *A. versicolor* isolates and 24 isolates of other *Aspergillus* species). Antifungal susceptibility testing was performed by the Clinical and Laboratory Standards Institute (CLSI) M38-A broth dilution method with itraconazole (ITR), posaconazole (POS), ravuconazole (RAV), and voriconazole (VOR). We examined the potential for cross-resistance by using measures of correlation overall and by species. For most *Aspergillus* isolates (from 88% of isolates for ITR to 98% of isolates for VOR and POS), MICs of each triazole were  $\leq 1$   $\mu\text{g/ml}$ . When all 771 isolates were examined, there were statistically significant correlations for all six triazole-triazole pairs. For *A. fumigatus*, the strongest correlations seen were those between VOR and RAV MICs ( $r = 0.7$ ) and ITR and POS MICs ( $r = 0.4$ ). Similarly, for *A. flavus*, only VOR and RAV MICs and ITR and POS MICs demonstrated statistically significant positive correlations. We have demonstrated correlations among triazole MICs for *Aspergillus*, which for the most common species (*A. fumigatus* and *A. flavus*) were strongest between VOR and RAV MICs and ITR and POS MICs. However, *Aspergillus* species for which MICs of VOR or POS were  $> 2$   $\mu\text{g/ml}$  remain extremely rare ( $< 1\%$  of isolates).

Azole resistance among *Aspergillus* spp. is uncommon. Denning and colleagues have shown maximum rates of itraconazole resistance (MIC  $\geq 4$   $\mu\text{g/ml}$ ) of 4.2% for *Aspergillus* spp. and 2.1% for *A. fumigatus* (6, 15). These findings are supported by those of Verweij et al. (21) and Diekema et al. (8). Clinical and in vivo resistance to itraconazole (5, 6) and elevated voriconazole MICs (20) for *A. fumigatus* clinical isolates have been described previously, and clear advances in defining the mechanisms of azole resistance in this species have been made (1, 2, 6, 9, 11–16, 22). However, no study has investigated azole cross-resistance in more than a handful of clinical *Aspergillus* isolates (15).

As part of our global antifungal resistance surveillance programs, we collected hundreds of clinical isolates of *Aspergillus* spp. from medical centers worldwide between 2000 and 2006. We used this large collection of clinical *Aspergillus* isolates to describe the patterns of in vitro activity of four azoles (itraconazole, voriconazole, posaconazole, and ravuconazole) against *Aspergillus* spp.

### MATERIALS AND METHODS

**Organisms.** A total of 771 unique patient clinical isolates of *Aspergillus* spp. were obtained from 62 different medical centers worldwide. The isolates were obtained from a variety of sources, including sputum, bronchoscopy, and tissue biopsy specimens. The collection of isolates included 553 *A. fumigatus*, 76 *A. flavus*, 59 *A. niger*, 35 *A. terreus*, and 24 *A. versicolor* isolates and 24 isolates of

other *Aspergillus* species. All isolates were identified using standard microscopic morphology and were stored as spore suspensions in sterile distilled water at room temperature until they were used in the study. Before testing, each isolate was subcultured at least twice on potato dextrose agar (Remel, Lenexa, KS) to ensure viability and purity. As a screen for cryptic species within the *A. fumigatus* complex (e.g., *A. lentulus*), all *A. fumigatus* isolates for which the MIC of any azole was  $\geq 2$   $\mu\text{g/ml}$  were tested for growth at 50°C. All isolates screened grew at 50°C, confirmation that they were *A. fumigatus* rather than another species within the complex.

**Susceptibility testing.** Posaconazole (Schering-Plough), voriconazole (Pfizer), ravuconazole (Bristol-Myers Squibb), and itraconazole (Janssen) were all obtained as reagent-grade powders from their respective manufacturers. The broth microdilution method was performed according to the CLSI M38-A standard (3). Trays containing a 0.1-ml aliquot of the appropriate drug solution ( $2\times$  final drug concentration) in each well were sealed and stored at  $-70^\circ\text{C}$  until being used in the study. The stock conidial suspension ( $10^6$  spores/ml) was diluted to a final inoculum concentration of  $0.4 \times 10^4$  to  $5 \times 10^4$  CFU/ml and dispensed into the microdilution wells. The final concentrations of drugs in the wells ranged from 0.008 to 8.0  $\mu\text{g/ml}$ . The inoculated microdilution trays were incubated at 35°C and read at 48 h. The MIC end point for the azoles was defined as the lowest concentration that produced the complete inhibition of growth.

In the absence of azole breakpoints for the filamentous fungi, we used the following provisional breakpoints for all agents tested: susceptible, MIC  $\leq 1$   $\mu\text{g/ml}$ ; intermediate, MIC = 2  $\mu\text{g/ml}$ ; and resistant, MIC  $\geq 4$   $\mu\text{g/ml}$ .

**Quality control.** Quality control was ensured by testing the following strains recommended in the CLSI M38-A document: *A. flavus* ATCC 204304, *Candida parapsilosis* ATCC 22019, and *Candida krusei* ATCC 6258.

**Statistical methods.** We examined correlations between the MICs of each azole-azole combination by using the Pearson correlation coefficient. SPSS software version 13 (SPSS, Chicago, IL) was used for statistical analyses.

### RESULTS AND DISCUSSION

Antifungal susceptibility test results for all four azoles against the 771 isolates of *Aspergillus* spp. are displayed in Table 1. Posaconazole and voriconazole were the most active agents in vitro, with 98% of isolates inhibited at an MIC of  $\leq 1$

\* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242. Phone: (319) 356-8615. Fax: (319) 356-4916. E-mail: michael-pfaller@uiowa.edu.

<sup>∇</sup> Published ahead of print on 18 June 2008.

TABLE 1. In vitro susceptibilities of 771 isolates of *Aspergillus* spp. to four azole antifungal agents

Species (no. of isolates)	Antifungal agent	MIC (µg/ml)		Cumulative % of isolates inhibited at MIC (µg/ml) of:								
		Range	50%/90%	0.03	0.06	0.12	0.25	0.5	1	2	4	8
<i>A. fumigatus</i> (553)	Itraconazole	0.12–2	0.5/1	0	0	3	17	51	93	100		
	Posaconazole	0.03–2	0.25/0.5	4	17	37	79	97	99	100		
	Ravuconazole	0.06–4	0.5/0.5	0	<1	3	34	92	99	>99	100	
	Voriconazole	0.06–4	0.25/0.5	0	<1	13	81	98	>99	>99	100	
<i>A. flavus</i> (76)	Itraconazole	0.12–2	0.5/1	0	0	1	20	80	99	100		
	Posaconazole	0.06–2	0.25/0.5	0	1	25	75	93	97	100		
	Ravuconazole	0.12–2	0.5/1	0	0	1	12	50	99	100		
	Voriconazole	0.06–1	0.5/1	0	1	4	22	75	100			
<i>A. niger</i> (59)	Itraconazole	0.5–>8	2/>8	0	0	0	0	10	41	76	78	78
	Posaconazole	0.12–2	0.25/1	0	0	19	58	85	92	100		
	Ravuconazole	0.25–8	2/4	0	0	0	3	14	46	88	98	100
	Voriconazole	0.12–2	0.5/1	0	0	3	12	53	97	100		
<i>A. terreus</i> (35)	Itraconazole	0.12–1	0.5/0.5	0	0	6	34	97	100			
	Posaconazole	0.06–0.5	0.25/0.25	0	9	49	94	100				
	Ravuconazole	0.03–1	0.5/0.5	3	3	9	40	94	100			
	Voriconazole	0.06–1	0.25/0.5	0	3	6	54	94	100			
<i>A. versicolor</i> (24)	Itraconazole	0.12–>8	1/2	0	0	4	17	33	67	96	96	96
	Posaconazole	0.06–2	0.5/1	0	8	21	46	75	92	100		
	Ravuconazole	0.03–2	0.5/1	8	8	25	38	67	96	100		
	Voriconazole	0.03–2	0.25/1	4	8	21	67	75	96	100		
<i>A. nidulans</i> (5)	Itraconazole	0.5–0.5	0.5/NA <sup>c</sup>	0	0	0	0	100				
	Posaconazole	0.06–0.25	0.12/NA	0	20	80	100					
	Ravuconazole	0.03–2	0.12/NA	40	40	80	80	80	80	100		
	Voriconazole	0.03–2	0.12/NA	40	40	80	80	80	80	100		
<i>A. sydowii</i> (4)	Itraconazole	0.5–4	2/NA	0	0	0	0	25	25	75	100	
	Posaconazole	0.25–1	0.25/NA	0	0	0	50	75	100			
	Ravuconazole	0.25–2	0.25/NA	0	0	0	50	50	75	100		
	Voriconazole	0.25–2	0.25/NA	0	0	0	50	75	75	100		
<i>A. calidoustus</i> ( <i>A. ustus</i> ) <sup>a</sup> (4)	Itraconazole	0.12–2	2/NA	0	0	25	25	25	25	100		
	Posaconazole	0.25–8	2/NA	0	0	0	25	25	25	50	75	100
	Ravuconazole	0.25–2	1/NA	0	0	0	25	25	50	100		
	Voriconazole	0.25–4	2/NA	0	0	0	25	25	25	75	100	
All <i>Aspergillus</i> isolates <sup>b</sup> (771)	Itraconazole	0.12–>8	0.5/2	0	0	3	17	53	88	98	98	98
	Posaconazole	0.03–>8	0.25/0.5	3	13	34	76	95	98	>99	>99	>99
	Ravuconazole	0.03–>8	0.5/1	1	1	4	30	80	94	99	>99	>99
	Voriconazole	0.03–>8	0.25/0.5	1	1	12	67	90	98	>99	>99	>99

<sup>a</sup> Formerly identified as *A. ustus* (19).

<sup>b</sup> In addition to the species in the table, the total includes two *A. glaucus* isolates, one *A. oryzae* isolate, and one *A. niveus* isolate.

<sup>c</sup> NA, not applicable.

µg/ml, while itraconazole was the least active, with 88% of isolates inhibited at an MIC of ≤1 µg/ml.

Table 2 details the distributions of MIC<sub>50</sub>s, MIC<sub>90</sub>s, and MICs of posaconazole, ravuconazole, and voriconazole with respect to the itraconazole MICs. For each of the newer azoles, the MIC increased as the itraconazole MIC increased. Scattergrams of the relationships between itraconazole and other azole MICs are presented in Fig. 1.

When all 771 isolates were examined, there were statistically significant correlations for all six triazole-triazole pairs (data not shown). Table 3 lists the azole-azole pairs with the most strongly correlated MICs for each of the most common species. For the three most common species, *A. fumigatus*, *A. flavus*, and *A. niger*, the strongest MIC correlations seen were

those for ravuconazole and voriconazole and for itraconazole and posaconazole.

Despite correlations between all azole-azole MICs, when itraconazole-resistant isolates (*n* = 17) were examined, the MICs of posaconazole and voriconazole for most of these isolates (94 and 88%, respectively) were ≤1 µg/ml. By contrast, the MIC of ravuconazole was ≤1 µg/ml for only 1 (6%) of 17 itraconazole-resistant isolates.

Resistance to the triazole antifungal agents is uncommon among clinical isolates of *Aspergillus* spp. (6, 15). Most studies concerning mechanisms of azole resistance in *Aspergillus* have been performed with *A. fumigatus* and have demonstrated that resistance was associated with the modification of the 14-α sterol demethylase target enzyme (CYP51), specifically, mod-

TABLE 2. In vitro susceptibilities of 771 isolates of *Aspergillus* spp. to posaconazole, ravuconazole, and voriconazole with respect to itraconazole susceptibility

Itraconazole category (no. of isolates)	Antifungal agent	MIC ( $\mu\text{g/ml}$ )		Cumulative % of isolates inhibited at MIC ( $\mu\text{g/ml}$ ) of:								
		Range	50%/90%	0.03	0.06	0.12	0.25	0.5	1	2	4	8
Susceptible (MIC $\leq$ 1 $\mu\text{g/ml}$ ) (680)	Posaconazole	0.03–2	0.25/0.5	3	15	37	81	97	99	100		
	Ravuconazole	0.03–4	0.5/1	1	1	5	34	85	99	>99	100	
	Voriconazole	0.03–4	0.25/0.5	1	2	13	72	94	>99	>99	100	
Intermediate (MIC = 2 $\mu\text{g/ml}$ ) (74)	Posaconazole	0.06–8	0.5/1	0	4	8	37	74	91	97	99	100
	Ravuconazole	0.25–4	0.5/2	0	0	0	5	51	74	99	100	
	Voriconazole	0.12–4	0.5/2	0	0	3	38	68	89	97	100	
Resistant (MIC $\geq$ 4 $\mu\text{g/ml}$ ) (17)	Posaconazole	0.12–>8	0.25/1	0	0	29	77	82	94	94	94	94
	Ravuconazole	1–>8	2/8	0	0	0	0	0	6	59	88	94
	Voriconazole	0.25–>8	1/2	0	0	0	6	24	88	94	94	94

ification corresponding to mutations in the gene *cyp51A* (1, 2, 6, 9, 11–16). Importantly, mutations resulting in resistance to posaconazole and itraconazole appear to differ from those conferring resistance to voriconazole and ravuconazole (12, 14, 17, 22). Cross-resistance to itraconazole and posaconazole has been associated with amino acid substitutions at glycine 54 (G54) (7, 12, 16, 17), whereas cross-resistance to voriconazole and ravuconazole has been associated with amino acid substitutions at G448 (13, 22). It has been postulated previously, based on results from molecular modeling studies, that a substitution at G54 in the  $\alpha$  helix of *A. fumigatus* CYP51A (AfCYP51A) confers resistance to posaconazole and itraconazole by perturbing the binding of the long side chain in the hydrophobic channel (channel 2) of the enzyme (22). Given that voriconazole and ravuconazole lack a long side chain, substitutions at G54 would be predicted to have no effect on the binding of these compact triazoles to the target. Conversely, substitution near the heme cofactor (e.g., at G448) would disturb the binding of voriconazole and ravuconazole to a greater extent than that of posaconazole and itraconazole due to the stabilizing influence of the side chain present in the latter two agents (22).

Recently, a third pattern of azole resistance in *A. fumigatus* was reported (7, 12, 16). This new pattern is characterized by high MICs of itraconazole, voriconazole, ravuconazole, and posaconazole. The majority of strains with this phenotype harbor amino acid substitutions at methionine 220 (M220) (13, 17). The role of the M220 substitutions in multiazole resistance was confirmed by Mellado et al., who introduced mutated *cyp51A* genes into an *A. fumigatus* wild-type strain, with resulting resistance to all triazole agents (13). They also detected M220 substitutions in five clinical isolates of *A. fumigatus* that exhibited the multiazole-resistant phenotype. Thus, it appears that the ways in which the various mutations in AfCYP51A impact the susceptibility to specific azoles reflect differences in the ways the azoles interact with the target protein.

An additional mechanism of resistance to azoles in *A. fumigatus* is reduced intracellular accumulation of the drugs. This mechanism was first demonstrated in laboratory-derived itraconazole-resistant mutants of *A. fumigatus* in which the reduced accumulation of itraconazole was postulated to be due to either diminished permeability or defects in an energy-dependent uptake process (11). More recently, Nascimento et

al. found that in addition to a mutation at G54 in the AfCYP51A target, itraconazole-resistant isolates of *A. fumigatus* exhibited high-level expression of two genes, *AfMDR3* and *AfMDR4*, which encode drug efflux pumps (16). As in other fungi, it appears that multiple resistance mechanisms in *A. fumigatus* are involved in resistance to the triazole antifungal agents.

Few studies have investigated azole cross-resistance in more than a handful of clinical *Aspergillus* isolates (15). A large in vitro survey that included 6,423 clinical isolates and 10 species of *Aspergillus* demonstrated superior potencies of both posaconazole and voriconazole over that of itraconazole; however, no analysis of cross-resistance was provided (18). In a study of 338 Spanish clinical isolates of *Aspergillus* spp., Gomez-Lopez et al. (10) demonstrated comparable in vitro activities of itraconazole and voriconazole. Among the 12 isolates for which the itraconazole MIC was  $\geq$ 4  $\mu\text{g/ml}$ , the voriconazole MIC was  $\geq$ 2  $\mu\text{g/ml}$  for 8 isolates (MIC range, 2 to 8  $\mu\text{g/ml}$ ), suggesting some degree of cross-resistance. Likewise, Cuenca-Estrella et al. (4) compared the activities of itraconazole, posaconazole, and voriconazole against 697 isolates of *Aspergillus* spp. (seven species) and found all three azoles to be quite active, with posaconazole showing slightly greater potency (geometric mean [GM] MIC = 0.1  $\mu\text{g/ml}$ ) than either itraconazole (GM MIC = 0.33  $\mu\text{g/ml}$ ) or voriconazole (GM MIC = 0.48  $\mu\text{g/ml}$ ). Among nine itraconazole-resistant isolates, posaconazole was active (MIC < 1  $\mu\text{g/ml}$ ) against five isolates (55%). Cross-resistance involving all three azoles was observed for isolates of *A. fumigatus*, *A. niger*, *A. nidulans*, and other *Aspergillus* species. Mosquera and Denning (15) studied 11 isolates of *A. fumigatus* defined as resistant to itraconazole (MIC > 4  $\mu\text{g/ml}$ ) in vitro. They found that elevated itraconazole MICs were uniformly associated with elevations in posaconazole MICs of 4- to 256-fold but that elevated itraconazole MICs were not usually associated with elevated MICs of ravuconazole or voriconazole. The patterns of susceptibilities of the isolates to voriconazole and ravuconazole were similar, suggesting similar modes of action and mechanisms of resistance. These findings suggest considerable heterogeneity in azole susceptibility among isolates of *A. fumigatus* (15). Most recently, Rodriguez-Tudela et al. examined cross-resistance among 393 *A. fumigatus* isolates, including 32 that were itraconazole resistant (MIC, >4  $\mu\text{g/ml}$  by the method of the Eu-




FIG. 1. Scatterplots of posaconazole (a), ravuconazole (b), and voriconazole (c) MICs versus itraconazole MICs for 771 clinical isolates of *Aspergillus* spp.

ropean Committee on Antimicrobial Susceptibility Testing) (17). Their findings confirmed that the cross-resistance pattern depends upon the specific mutation present, with G54 mutants displaying cross-resistance to itraconazole and posaconazole

TABLE 3. Strongest species-specific correlations between MICs of four azoles, by species

Species	No. of isolates tested	Agents for which MICs were correlated <sup>a</sup>	Pearson correlation coefficient	P value
<i>A. fumigatus</i>	553	RAV and VOR	0.72	<0.001
		ITR and POS	0.41	<0.001
<i>A. flavus</i>	76	RAV and VOR	0.43	<0.001
		ITR and POS	0.31	0.006
<i>A. niger</i>	59	ITR and RAV	0.58	<0.001
		RAV and VOR	0.47	<0.001
<i>A. terreus</i>	35	RAV and VOR	0.55	0.001
<i>A. versicolor</i>	24	RAV and VOR	0.90	<0.001
		RAV and POS	0.77	<0.001

<sup>a</sup> Abbreviations: RAV, ravuconazole; VOR, voriconazole; ITR, itraconazole; POS, posaconazole.

while M220 mutants display cross-resistance to all four azoles tested (17).

Our findings confirm the in vitro potencies of the new and investigational azoles (voriconazole, posaconazole, and ravuconazole) against *Aspergillus* spp. The excellent in vitro activities of these agents limited our ability to examine the true patterns of cross-resistance. The patterns of in vitro susceptibilities we describe correspond to isolates for which azole MICs span a wide spectrum, with the MICs for most organisms (>98%) falling into a range ( $\leq 1$  µg/ml) that most would consider to indicate susceptibility to the tested agent. Despite this limitation, we have demonstrated that there is significant correlation among the MICs of all four azoles examined. In addition, we found that the azoles whose MICs for the two most common species groups correlated most strongly were ravuconazole and voriconazole and itraconazole and posaconazole. However, when we examined only those isolates for which the MICs of itraconazole were highest ( $\geq 4$  µg/ml), we did not find that they were predictably resistant to posaconazole or voriconazole; in fact, the MICs of posaconazole and voriconazole for most of these isolates were  $\leq 1$  µg/ml.

Unfortunately, there are no data available to assess the clinical impact of different in vitro resistance profiles among *Aspergillus* spp. However, the available data on resistance mechanisms and MIC correlations suggest not only that one may see correlations between voriconazole and ravuconazole MICs and itraconazole and posaconazole MICs but also that some resistance mutations may result in resistance to all four agents. At this time, given the fact that individual variations in MICs are not predictable, in vitro testing of the susceptibilities of clinical isolates to each of the triazoles is likely to be useful and may allow one to select the most active agent (15).

ACKNOWLEDGMENTS

This study was supported in part by research and educational grants from Pfizer Pharmaceuticals and Schering-Plough Research Institute.

We thank all the participating centers who contributed isolates to this study, a list of which can be found at the following URL: [http://www.healthcare.uiowa.edu/pathology/site/faculty/pfaller/artemis\\_participants.pdf](http://www.healthcare.uiowa.edu/pathology/site/faculty/pfaller/artemis_participants.pdf).



## REFERENCES

- Balashov, S. V., R. Gardiner, S. Park, and D. S. Perlin. 2005. Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the *cyp51A* gene of *Aspergillus fumigatus* that confer resistance to itraconazole. *J. Clin. Microbiol.* **43**:214–222.
- Chen, J., H. Li, R. Li, D. Bu, and Z. Wan. 2005. Mutations in the *cyp51A* gene and susceptibility to itraconazole in *Aspergillus fumigatus* serially isolated from a patient with lung aspergilloma. *J. Antimicrob. Chemother.* **55**:31–37.
- Clinical and Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. CLSI, Wayne, PA.
- Cuenca-Estrella, M., A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzon, and J. L. Rodriguez-Tudela. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. *Antimicrob. Agents Chemother.* **50**:917–921.
- Dannaoui, E., E. Borel, F. Persat, M. F. Monier, M. A. Piens, et al. 1999. In-vivo itraconazole resistance of *Aspergillus fumigatus* in systemic murine aspergillosis. *J. Med. Microbiol.* **48**:1087–1093.
- Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance in *Aspergillus fumigatus*. *Antimicrob. Agents Chemother.* **41**:1364–1368.
- Diaz-Guerra, T. M., E. Mellado, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2003. A point mutation in the 14 $\alpha$ -sterol demethylase gene *cyp51A* contributes to itraconazole resistance in *Aspergillus fumigatus*. *Antimicrob. Agents Chemother.* **47**:1120–1124.
- Diekema, D. J., S. A. Messer, R. J. Hollis, R. N. Jones, and M. A. Pfaller. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. *J. Clin. Microbiol.* **41**:3623–3626.
- Garcia-Effron, G., E. Mellado, A. Gomez-Lopez, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2005. Differences in interactions between azole drugs related to modifications in the 14 $\alpha$ -sterol demethylase gene (*cyp51A*) of *Aspergillus fumigatus*. *Antimicrob. Agents Chemother.* **49**:2119–2121.
- Gomez-Lopez, A., G. Garcia-Effron, E. Mellado, A. Monzon, J. L. Rodriguez-Tudela, and M. Cuenca-Estrella. 2003. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of *Aspergillus* spp. *Antimicrob. Agents Chemother.* **47**:3085–3088.
- Manavathu, E. K., J. A. Vazquez, and P. H. Chandrasekar. 1999. Reduced susceptibility in laboratory-selected mutants of *Aspergillus fumigatus* to itraconazole due to decreased intracellular accumulation of the antifungal agent. *Int. J. Antimicrob. Agents* **12**:213–219.
- Mann, P. A., R. M. Parmegiani, S. Q. Wei, C. A. Mendrick, X. Li, D. Loebenberg, B. DiDomenico, R. S. Hare, S. S. Walker, and P. M. McNicholas. 2003. Mutations in *Aspergillus fumigatus* resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14 $\alpha$ -demethylase. *Antimicrob. Agents Chemother.* **47**:577–581.
- Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2004. Substitutions at methionine 220 in the 14 $\alpha$ -sterol demethylase (*Cyp51A*) of *Aspergillus fumigatus* are responsible for resistance in vitro to azole antifungal drugs. *Antimicrob. Agents Chemother.* **48**:2747–2750.
- Mellado, E., G. Garcia-Effron, M. J. Buitrago, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2005. Targeted gene disruption of the 14 $\alpha$ -sterol demethylase (*cyp51A*) in *Aspergillus fumigatus* and its role in azole drug susceptibility. *Antimicrob. Agents Chemother.* **49**:2536–2538.
- Mosquera, J., and D. W. Denning. 2002. Azole cross-resistance in *Aspergillus fumigatus*. *Antimicrob. Agents Chemother.* **46**:556–557.
- Nascimento, A. M., G. H. Goldman, S. Park, S. A. Marras, G. Delmas, U. Oza, K. Lolans, M. N. Dudley, P. A. Mann, and D. S. Perlin. 2003. Multiple resistance mechanisms among *Aspergillus fumigatus* mutants with high-level resistance to itraconazole. *Antimicrob. Agents Chemother.* **47**:1719–1726.
- Rodriguez-Tudela, J. L., L. Alcazar-Fuoli, E. Mellado, A. Alastruey-Izquierdo, A. Monzon, and M. Cuenca-Estrella. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in *Aspergillus fumigatus*. *Antimicrob. Agents Chemother.* **52**:2468–2472.
- Sabatelli, F., R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNicholas. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. *Antimicrob. Agents Chemother.* **50**:2009–2015.
- Varga, J., J. Houbraeken, H. A. Van Der Lee, P. E. Verweij, and R. A. Samson. 2008. *Aspergillus calidoustus* sp. nov., causative agent of human infections previously assigned to *Aspergillus ustus*. *Eukaryot. Cell* **7**:630–638.
- Verweij, P. E., M. Mensink, A. J. Rijs, J. P. Donnelly, J. F. Meis, and D. W. Denning. 1998. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental *Aspergillus fumigatus* isolates. *J. Antimicrob. Chemother.* **42**:389–392.
- Verweij, P. E., D. T. Te Dorsthorst, A. J. Rijs, H. G. De Vries-Hospers, and J. F. Meis. 2002. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical *Aspergillus fumigatus* isolates cultured between 1945 and 1998. *J. Clin. Microbiol.* **40**:2648–2650.
- Xiao, L., V. Madison, A. S. Chau, D. Loebenberg, R. E. Palermo, and P. M. McNicholas. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14 $\alpha$ -sterol demethylases from *Aspergillus fumigatus* and *Candida albicans* provide insights into posaconazole binding. *Antimicrob. Agents Chemother.* **48**:568–574.